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Background: Activation of the ileal brake by casein induces satiety signals and reduces energy intake.
However, adverse effects of intraileal casein administration have not been studied before. These adverse
effects may include impaired amino acid digestion, absorption and immune activation.
Objective: To investigate the effects of intraileal infusion of native casein on plasma amino acid
appearance, immune activation and gastrointestinal (GI) symptoms.
Design: A randomized single-blind cross over study was performed in 13 healthy subjects (6 male; mean
age 26 ± 2.9 years; mean body mass index 22.8 ± 0.4 kg/m2), who were intubated with a naso-ileal
feeding catheter. Thirty minutes after intake of a standardized breakfast, participants received an ileal
infusion, containing either control (C) consisting of saline, a low-dose (17.2 kcal) casein (LP) or a high-
dose (51.7 kcal) of casein (HP) over a period of 90 min. Blood samples were collected for analysis of
amino acids (AAs), C-reactive protein (CRP), pro-inﬂammatory cytokines and oxylipins at regular in-
tervals. Furthermore, GI symptom questionnaires were collected before, during and after ileal infusion.
Results: None of the subjects reported any GI symptoms before, during or after ileal infusion of C, LP and
HP. Plasma concentrations of all AAs analyzed were signiﬁcantly increased after infusion of HP as
compared to C (p < 0.001), and most AAs were increased after infusion of LP (p < 0.001). In total,
12.49 ± 1.73 and 3.18 ± 0.87 g AAs were found in plasma after intraileal infusion of HP and LP, corre-
sponding to 93 ± 13% (HP) and 72 ± 20% (LP) of AAs infused as casein, respectively. Ileal casein infusion
did not affect plasma concentrations of CRP, IL-6, IL-8, IL-1b and TNF-a. Infusion of HP resulted in a
decreased concentration of 11,12-dihydroxyeicosatrienoic acid whereas none of the other oxylipins
analyzed were affected.
Conclusions: A single intraileal infusion of native casein results in a concentration and time dependent
increase of AAs in plasma, suggesting an effective digestion and absorption of AAs present in casein. Also,
ileal infusion did not result in immune activation nor in GI symptoms.
Clinicaltrials.gov: NCT01509469.
© 2016 The Authors. Published by Elsevier Ltd and European Society for Clinical Nutrition and
Metabolism. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).r the curve; ANOVA, mixed
; CV, coefﬁcient of variation;
; PYY, peptide YY; HP, high
8, interleukin-8; LLOQ, lower
w protein; RYGP, Roux-en-Y
-a, tumor necrosis factor-a.
x 360, 3700 AJ, Zeist, The
Ltd and European Society for Clini
d/4.0/).
, et al., Intraileal casein infu
n (2016), http://dx.doi.org/11. Introduction
The increasing prevalence of overweight causes increased con-
cerns for health and health care costs worldwide. There is a clear
need for therapeutic and preventive strategies, as current strategies
have not proven to be successful on the long term.
One potential strategy to reduce energy intake is activation of
the so-called ileal brake. The ileal brake is a feedback mechanismcal Nutrition and Metabolism. This is an open access article under the CC BY-NC-ND
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Table 1
Amino acid composition of native casein expressed as %
(w/w).
Amino acid % (w/w)
Glutamic acida 18.60
Proline 9.21
Leucine 8.09
Lysine 6.95
Aspartic acida 6.11
Valine 5.55
Serine 4.89
Tyrosine 4.57
Phenylalanine 4.35
Isoleucine 4.33
Threonine 3.68
Arginine 3.08
Alanine 2.62
Histidine 2.40
Methionine 2.22
Glycine 1.56
Tryptophan 1.15
Cysteine 0.39
Total 89.75
a The amino acid composition of casein was analyzed
by acid protein hydrolysis followed by amino acid
analysis using ninhydrin according to ISO 13903:2005.
This analytical method is unable to separate aspartic
acid from asparagine and glutamic acid from gluta-
mine. Tryptophan and cysteine were analyzed accord-
ing the EU152/2008 (F) and ISO 13903:2005 protocol.
D. Ripken et al. / Clinical Nutrition xxx (2016) 1e72that slows or ‘brakes’ the process of proximal gastrointestinal
digestion and absorption, and food intake. The ileal brake is acti-
vated when energy-containing macronutrients reach the ileum.
Ileal brake activation induces enhanced satiety signals, satiation
and reduction of energy intake [1,2]. Recently, we have shown that
not only ileal appearance of lipid but also of the other macronu-
trients, carbohydrate (sucrose) and protein (casein), results in
increased satiation and a reduction of food intake [3]. This reduc-
tion in food intake underlines the relevance of the ileal brake as
potential food based strategy in the prevention or treatment of
overweight and obesity. Despite its potential, it should be investi-
gated whether undigested native protein infused into the ileum
does not result in adverse effects such as protein malabsorption or
immune activation.
Intraileal infusion bypasses the proximal parts of the gastroin-
testinal (GI) tract as is also achieved by bariatric surgery. One of the
most frequently applied bariatric procedures worldwide is the
Roux-en-Y gastric bypass (RYGB). RYGB effectively results in weight
loss and improvement of type II diabetes [4]. Although the mech-
anism is not completely understood yet, the proposed mechanism
by which RYGB may exert its beneﬁcial effects is enhanced stimu-
lation of enteroendocrine cells in the distal small intestine by un-
digested nutrients, resulting in the release of the L-cell products
glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) [5]. It has
been suggested that weight loss after RYGB may be attributable to
limited food intake which can be partly explained by gastric re-
striction and malabsorption. However, evidence has increased that
the positive health effects induced by RYGB may be due to altered
GI physiology [4] and not due to gastric restriction and malab-
sorption. RYGB results in rapid emptying of gastric content with
prolonged small intestinal transit times [6] and only a small pro-
portion of the reduction in energy intake after RYGB is due to
malabsorption [7]. Malabsorption may result in an increased risk of
developing nutritional deﬁciencies, such as protein deﬁciency [8].
Under physiological conditions, gastric acid activates the conver-
sion of pepsinogen into the proteolytic enzyme pepsin which de-
natures orally ingested protein. Protein is further digested by
trypsin in the small intestine. In response to orally ingested protein,
amino acids in the form of peptides or free amino acids are found in
the intraluminal content of the jejunum and ileum [9].
Recently it was found by Bojsen-Møller et al. (2015) that RYGB
accelerates caseinate digestion and amino acid absorption, and it
was suggested that protein digestion is not impaired after RYGB
[10]. However, it remains to be investigated whether native casein,
directly infused into the ileum and thus bypassing the proximal
parts of the small intestine results in malabsorption. If this is the
case, protein may be available for colonic fermentation resulting in
potential harmful effects for the host's health [11]. Such effect could
manifest itself by immune activation [12]. This might be shown by
the production and release of pro-inﬂammatory cytokines such as
interleukin-1b (IL-1b), IL-6, IL-8 and tumor necrosis factor-a (TNF-
a) [12], or other pro-inﬂammatory mediators such as C-reactive
protein (CRP) and eicosanoids, a subset of oxylipins. The release of
these lipid mediators can be triggered by a variety of stimuli. They
have been associated to be involved in pain and fever and are
known to be potent regulators of the host immune response [13,14].
The aim of this study was to investigate the effects of intraileal
native protein infusion on digestion, AA absorption and immune
activation. This was done in a study evaluating the effects of
intraileal infusion of native protein on food intake previously per-
formed by our group [3]. It was hypothesized that ileal infusion of
native casein results in plasma appearance of AAs in casein and
does not result in acute adverse effects such as incomplete diges-
tion of casein protein or inﬂammation. This was investigated by
analyzing plasma AAs at several time points after intraileal infusionPlease cite this article in press as: Ripken D, et al., Intraileal casein infu
randomized cross over trial, Clinical Nutrition (2016), http://dx.doi.org/1of both a low-dose and high-dose of casein in a randomized single-
blind cross over study as reported by van Avesaat et al. (2015) [3].
Inﬂammatory mediators such as pro-inﬂammatory cytokines and
oxylipins were analyzed to investigate acute adverse inﬂammatory
effects.
2. Material and methods
2.1. Study design
In the present study plasma samples from a previously pub-
lished single blind randomized placebo controlled cross over study
were analyzed to investigate the effects of intraileal protein infu-
sion on plasma proﬁles of AAs and inﬂammation markers [3].
Thirteen subjects (6 male, 7 female, age 26 ± 2.9 years, BMI of
22.8 ± 0.4 kg m2) completed the study.
The effects on AAs and inﬂammation markers of the following
interventions were investigated 1) saline infusion (control (C)), 2)
low dose protein infusion (5 g casein (LP), 17.2 kcal) and 3) high
dose protein infusion (15 g casein (HP), 51.7 kcal). Each treatment
was infused into the ileum over a 90-min period, on separate test
days. Order of interventions were randomly assigned to each
participant and based on a randomization protocol (via randomizer.
org) deﬁned prior to the start of the study.
Casein (energy density: 3.45 kcal/g, Dutch Protein & Services,
Tiel, The Netherlands) was used as protein source. The AA
composition of casein is shown in Table 1 (Euroﬁns Food Testing
Netherlands B.V., Heerenveen, The Netherlands). Casein was dis-
solved in a total volume of 180 ml tap water and infused into the
ileum a rate of 2 ml/min (0.6 kcal/min; total infusion time 90 min).
2.2. Experimental design
Each subject participated in all three test days. On all test days
an intravenous catheter was placed in a forearm vein for blood
collection. At 8.30 AM, a basal blood sample was obtained. Subse-
quently, a standardized breakfast meal consisting of a sandwichsion increases plasma concentrations of amino acids in humans: A
0.1016/j.clnu.2016.01.012
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infusion was performed from t ¼ 30 to t ¼ 120 min after breakfast
ingestion. Participants were blinded to the infusion treatment. One
hour after ending the infusion (t¼ 180 min), the volunteer received
a standardized ad libitum lunch meal (sandwiches with egg salad
(energy density: 2.2 kcal/g)). At t ¼ 240 the last blood sample was
taken and the test day was ﬁnished.
2.3. Questionnaires
GI symptoms were evaluated using a questionnaire addressing
complaints such as headache, nausea, stomach-ache, diarrhea, and
other symptoms. Symptoms were graded on a 4-point scale with
the grade 0 representing ‘not present’ to 4 ‘strongly present’. Sub-
jects were asked tomark how they felt at themoment before (t¼ 15
and t ¼ 30), during (t ¼ 60 and t ¼ 90) and after the infusion
stopped (t ¼ 120 and t ¼ 240).
2.4. Sample collection
Venous blood samples were drawn 15 min before breakfast
(t ¼ 15 min), and at 30, 45, 60, 90, 120, 150, 180, 210 and 240 min
after breakfast, respectively. Blood was collected in ice-chilled
EDTA coated tubes (Becton & Dickinson, Franklin Lakes, NJ, USA).
Immediately after blood collection, tubes were centrifuged at a rate
of 3000 revolutions per minute at 4 C for 10 min. Plasma was
transferred into aliquots and stored on dry ice for the rest of the test
day. At the end of the test day, samples were stored at 80 C until
further analysis of AAs, cytokines and oxylipins.
2.5. Plasma amino acid proﬁles
Plasma AA proﬁles were analyzed including the AAs present in
casein (Table 1, except cysteine), as well as other AAs and amines,
i.e. 1-methylhistidine, 3-methylhistidine, asymmetric dimethy-
larginine, citrulline, DL-3-amino isobutylene, glycyl-glycine, homo-
arginine, hydroxyl-lysine, amino adipic acid, a-amino-n-butyric
acid, kynurenine, L-4-hydroxy-proline, L-glutamic acid, homo-
serine, trimethylamine, phosphor-ethanolamine, putrescine,Table 2
Overview of oxylipins analyzed assigned to their precursor fatty acids.
Arachidonic acid Dihomo-g-linoleic acid
Prostanoids/thromboids TXB2 PGF1a
PGF2a
PGE2
13,14-Dihydro-PGF2a
Diols 14,15-DiHETrE
11,12-DiHETrE
8,9-DiHETrE
5,6-DiHETrE
Epoxides
Alcohols 12-HETE
5-HETE
15-HETE
20-HHETE
11-HETE
Ketones
Triols
Please cite this article in press as: Ripken D, et al., Intraileal casein infu
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gamma-aminobutyrine, gamma-L-glutamyl amine, glycine,
ethanol, glutamine, o-acetyl-L-serine. AAs and amines were
analyzed using an LCeMS method as described previously [16].2.6. Plasma proﬁles of pro-inﬂammatory cytokines and C-reactive
protein
Plasma proﬁles of CRP, TNF-a, IL-1b, IL-6, IL-8 were analyzed
using an in-house developed and validated multiplex immuno-
assay based on Luminex technology (xMAP, Luminex, Austin TX
USA). The assay was performed as described previously [17,18].
Aspeciﬁc heterophilic immunoglobulins were pre-absorbed from
all samples with heteroblock (Omega biologicals Bozeman MT,
USA). Acquisition was performed with the Biorad FlexMAP3D
(Biorad laboratories, Hercules USA) in combination with xPONENT
software version 4.2 (Luminex). Data were analyzed by 5-
parametric curve ﬁtting using Bio-Plex Manager software, version
6.1.1 (Biorad).
For TNF-a the range was 1.2e5000 pg/ml and the limit of
detection (LOD) for TNF-a was 0.7 pg/ml, with an inter-assay co-
efﬁcient of variation (CV) of 3.0 ± 1.8% and an intra-assay CV of
7.6 ± 0.6%. For IL-1b the range of the assay was 1.2e5000 pg/ml and
the LOD was 0.4 pg/ml with an intra-assay CV of 3.4 ± 2.9% and an
inter-assay of 3.5 ± 2.5%. For IL-6 the range of the assay was
2.4e10,000 pg/ml and the LOD for IL-6was 0.9 pg/ml, with an intra-
assay CV of 4.4 ± 2.7% and an inter-assay CV of 11.0 ± 4.6%. For IL-8
the range of the assay was 2.4e10000 pg/ml and the LOD was
1.3 pg/ml with an intra-assay CV of 5.8 ± 3.6% and inter-assay CV of
13.7 ± 6.8%. For CRP the range was 12.2e50,000 pg/ml and the LOD
was 11.7 pg/ml whereas the upper limit of detection was
42,691.6 pg/ml. The samples were diluted to be within the range of
the assay.
Not all cytokine concentrations were above the lower limit of
quantiﬁcation (LLOQ) of the assay. For TNF-a, 63% of the samples
was below the LLOQ (1.2 pg/ml). For IL-1b, 25% of the samples was
below the LLOQ (2.2 pg/ml). For IL-6, 11% of the samples was below
LLOQ (2.8 pg/ml). For IL-8, 46% of the samples was below LLOQDocosahexa-enoic acid Eicosapenta-enoic acid Linoleic acid
19,20-DiHDPA 17,18-DiHETE 12,13-DiHOME
14,15-DiHETE 9,10-DiHOME
12(13)-EpOME
9,10-EpOME
17-HDoHE 12-HEPE 9-HODE
14-HDoHE 5-HEPE 13-HODE
10-HDoHE
13-KODE
9-KODE
9,12,13-TriHOME
9,10,13-TriHOME
sion increases plasma concentrations of amino acids in humans: A
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Fig. 1. Plasma proﬁles of proline (A), leucine (B), glutamic acid (C) and taurine (D) after
intraileal infusion (infusion time t ¼ 30e120 min) of control (C), low-dose casein
protein (LP) or high-dose casein (HP) (n ¼ 13). An interaction effect (treatment*time)
for proline (A) and leucine (B) was observed. Proline and leucine concentrations
increased after HP infusion (p < 0.0001) and LP infusion (p < 0.0001). Glutamic acid (C)
increased after HP infusion ($!treatment effect p < 0.005) as compared with both
placebo and LP infusion (this panel represents ratios of the peak area's/internal stan-
dard peak areas). Taurine concentrations (D) were not affected by HP or LP infusion.
*p < 0.05 compared with placebo at the same time point, **p < 0.0001 compared with
placebo at the same time point, !p < 0.001 compared with LP at the same time point.
Note: in Supplemental data Table 1 the results of all amino acids are presented.
D. Ripken et al. / Clinical Nutrition xxx (2016) 1e74(4.5 pg/ml). Since these samples were below the detection range of
the assay, they were excluded from the data analysis.
2.7. Plasma proﬁles of oxylipins
The oxylipin platform (Table 2) covers classical and non-classical
eicosanoids from different polyunsaturated fatty acids, includingu-
6 andu-3 PUFAs such as linoleic acid, arachidonic acid and dihomo-
g-linoleic acid (all u-6), eicosapentaenoic acid and docosahexae-
noic acid (both u-3). The samples were analyzed by liquid chro-
matography tandem mass spectrometry as described previously
[19].
2.8. Data analysis
Intervention effects on plasma AA concentrations, pro-
inﬂammatory cytokines and oxylipins were analyzed withinPlease cite this article in press as: Ripken D, et al., Intraileal casein infu
randomized cross over trial, Clinical Nutrition (2016), http://dx.doi.org/1participants with a mixed model analysis of variance (ANOVA)
including the ﬁxed factors treatment (infusion of C, infusion of LP
and infusion of HP), time and the interaction between treatment
and time. Because of the crossover design, intervention effects
within subjects were compared by including the random factor
subject.
All statistical analyses were performed using the SAS statistical
software package (SAS version 9; SAS institute, Cary, NC, USA). Data
were visually checked on normality and on constant variance of
residuals by plots of residuals vs. corresponding predicted values.
All data met the criteria for ANOVA assumptions. If an intervention
effect occurred post hoc comparisons were made using TukeyeK-
ramer adjustment to correct for multiple testing. Data are pre-
sented as the mean ± SEM (unless speciﬁed otherwise) and
considered signiﬁcant at p < 0.05.
Since infused amounts of native casein (5 g LP vs. 15 g HP) were
known, the amount of AAs infused as casein was calculated based
on the AA composition of the native casein infused (Table 1). To
calculate the absolute amount of AA in gram, plasma AA concen-
trations (mmol/L) were corrected for the total blood volume (female
65 ml/kg, male 75 ml/kg [20]). To estimate the increase in AAs due
to LP and HP infusion, the total area under the curves (AUCs) during
the infusion period (t ¼ 30 until t ¼ 180) were calculated by
applying the trapezoid method. The AUC after C treatment was
subtracted from AUCs after LP and HP infusion per individual to
correct for control AA concentrations. In case the AUC was negative
after placebo correction, the value was excluded from further
analysis (n ¼ 3 for LP and n ¼ 1 for HP).3. Results
3.1. Questionnaires
Subjects did not report any feelings of nausea, intestinal cramps,
diarrhea, headache, heartburn, belching or other parameters of
impaired wellbeing before, during or after infusion of C, LP or HP.3.2. Amino acid plasma concentrations
Baseline AA concentrations were not different between treat-
ments. Overall, a treatment and time interaction effect was found
(p < 0.001); AAs present in native casein increased after LP and HP
over time as compared to C (p < 0.001), whereas amines or me-
tabolites not present in casein such as taurine did not (Fig. 1 and
Supplemental data Tables 1 and 2). Post-hoc analysis showed that
both LP and HP resulted in increased plasma concentrations over
time as compared to C of 15 out of 19 analyzed AAs in casein,
namely alanine, arginine, asparagine, histidine, isoleucine, leucine,
lysine, methionine, phenylalanine, proline, serine, threonine,
tryptophan, tyrosine and valine (p < 0.001). Aspartic acid was only
increased after HP (p < 0.0001). Concentrations of glutamic acid
could not be assessed due to high plasma glutamic acid concen-
trations. Therefore these results are shown in relative peak areas as
compared to an internal standard of glutamic acid concentration
(Fig. 1C). Glutamic acid was increased after HP and LP as compared
to C (p < 0.005). Plasma concentrations of glutamine and glycine
did not change after LP and HP infusion.
HP resulted in a further increase of the following AAs as
compared to LP; aspartic acid, histidine, isoleucine, leucine, lysine,
methionine, phenylalanine, proline, tyrosine, tryptophan and
valine (p < 0.001). After infusion of LP and HP the AAs present in
native casein increasedwhen the infusion started (t¼ 30), and peak
plasma concentrations were reached at the time the infusion
stopped (t ¼ 120) (Fig. 1A, B). All other amines and AAs not presentsion increases plasma concentrations of amino acids in humans: A
0.1016/j.clnu.2016.01.012
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concentrations after LP, HP or C.
In Table 3 the mean AUCs (g) are shown per AA for LP and HP.
Also the total amount of AAs found in plasma after intraileal infu-
sion of LP and HP was calculated as a percentage of amount of AAs
infused as casein (4.44 g for LP and 13.38 g for HP). In total,
3.18 ± 0.87 g and 12.49 ± 1.73 g AAs were found in plasma after
intraileal infusion of LP and HP, respectively. These numbers
correspond to 72 ± 20% (LP) and 93 ± 13% (HP) of the amount of AAs
infused as casein.
3.3. Cytokines and CRP
Plasma concentrations of IL-6, IL-8, IL-1b, TNF-a and CRP were
not affected by either LP, HP or C (Fig. 2). Plasma concentrations of
the cytokines analyzed did not change over time and no interaction
effect between time and protein infusion was found.
3.4. Oxylipins
Only an effect of infusion (p < 0.001), time (p < 0.001) and
interaction between infusion and timewas found for 11,12-DiHETrE
(p < 0.05) (Fig. 3). Concentrations of 11,12-DiHETrE decreased after
HP (p < 0.001) and LP (p < 0.01) as compared to C. Plasma con-
centrations of 11,12-DiHETrE did not differ between LP as compared
to HP.
An infusion and time effect (p < 0.05) was found for 5,6-DiHETrE
and 19,20-DiHDPA. These oxylipins decreased after HP as compared
to C, and LP (p < 0.05). However, no interaction between time and
treatment was found.
None of the other oxylipins presented in Table 2 were affected
by ileal infusion of either LP, HP or C.
4. Discussion
To our knowledge this is the ﬁrst study showing that intraileal
infusion of native casein results in AA plasma recoveries ofTable 3
AAs in plasma AUCs (30e180 min) after C, LP and HP.
Amino acid LP (n ¼ 10)
Infused AA (as casein) AUC plasma AA
Mean (g) Mean (g) SEM p-value*
Alanine 0.13 0.44 0.18 ns
Arginine 0.15 0.56 0.12 <0.005
Aspartic acid 0.31 0.03
0.06
0.01
0.05
ns
ns
Asparagine
Glutamic acid 0.90 0.49 0.90 ns
ns
Glutamine
Glycine 0.08 0.18 0.12 ns
Histidine 0.12 0.31 0.12 <0.05
Isoleucine 0.22 0.23 0.08 ns
Leucine 0.40 0.38 0.13 ns
Lysine 0.35 0.47 0.29 ns
Methionine 0.11 0.04 0.03 ns
Phenylalanine 0.22 0.17 0.07 ns
Proline 0.46 0.26 0.18 ns
Serine 0.24 0.12 0.12 ns
Threonine 0.18 0.13 0.09 ns
Tryptophan 0.06 0.09 0.03 ns
Tyrosine 0.23 0.08 0.06 ns
Valine 0.28 0.44 0.23 ns
Total 4.44 3.18 0.87 ns
*p-value LP or HP as compared to C, #p-value as compared LP, ns; not signiﬁcant.
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native protein casein at 5 and 15 g may result in near complete
digestion and absorption of its AAs. Pro-inﬂammatory mediators or
GI symptoms did not increase in response to intraileal protein
infusion, indicating that intraileal casein infusion does not induce
adverse effects in healthy subjects.
The present study aimed to investigate adverse effects of
intraileal protein infusion. This was done by 1) estimating AA
digestion and absorption after LP and HP reducing the possibility of
casein malabsorption and 2) evaluating immune activation after
ileal protein infusion.
For casein speciﬁc AAs, plasma recoveries of 72 ± 20% and
93 ± 13% were estimated after LP and HP. It cannot be excluded that
part of the increased AA concentrations after LP and HP result from
endogenous protein breakdown. However the following arguments
suggest that the increase in casein speciﬁc AAs was due to intraileal
casein infusion; 1) data of the present study show reproducible and
dose-dependent AA concentration patterns after infusion of both LP
and HP for all AAs present in casein. In contrast, plasma concen-
trations of amines (e.g. taurine) not present in casein did not
change after infusion of both LP and HP; 2) Starting ileal protein
infusion resulted in an immediate increase in plasma AA concen-
trations, whereas these concentrations decreased immediately af-
ter ending the infusion; 3) Effects on AA plasma concentrations
were studied within subjects making direct comparisons between
undigested casein and saline possible.
In this study we showed that pro-inﬂammatory markers were
not affected by protein infusion, nor were GI symptoms. Subjects
did not report any feelings of nausea, intestinal cramps, diarrhea,
headache, heartburn, belching or other overall GI symptoms before,
during or after C, LP or HP. The results on subjective feelings of
wellbeing during intestinal protein infusion are in line previous
studies. In studies of Geraerts (2011) and Ryan et al. (2013) it was
shown that intraduodenally infused protein did not result in any GI
complaints [21,22].
Recently Neurath et al. proposed that factors in the diet such as
dietary protein may contribute to an impaired intestinal barrierHP (n ¼ 12)
Infused AA (as casein) AUC plasma AA
Mean (g) Mean (g) SEM p-value* p-value#
0.39 0.88 0.35 <0.05 ns
0.46 0.72 0.15 <0.0001 ns
0.92 0.09 0.04 <0.05 ns
0.14 0.05 ns ns
2.79 0.31 0.89 ns
ns
ns
ns
0.23 0.26 0.10 ns ns
0.36 0.40 0.10 0.0034 ns
0.65 0.81 0.12 <0.0001 <0.0001
1.21 1.52 0.30 <0.0001 <0.0001
1.04 2.35 0.59 0.0003 <0.005
0.33 0.28 0.04 <0.0001 <0.0001
0.65 0.28 0.06 <0.005 ns
1.38 0.26 0.18 <0.005 <0.005
0.73 1.11 0.25 <0.05 ns
0.55 0.55 0.14 0.0005 <0.05
0.17 0.33 0.07 <0.0001 <0.05
0.69 0.73 0.15 <0.0001 <0.0001
0.83 1.45 0.26 <0.0001 <0.005
13.38 12.49 1.73 <0.0001 <0.0001
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Fig. 2. Plasma concentrations of IL-6 (A), IL-8 (B), IL-1b (C), TNF-a (D) and CRP after
intraileal infusion (infusion time t ¼ 30e120 min) with control (C), low-dose casein
(LP) or high-dose casein (HP). None of the treatments affected plasma concentrations
of the cytokines analyzed. For IL-6, 2 subjects plasma concentrations were below the
LLOQ (n ¼ 11). For IL-8, 8 subjects plasma concentrations were below the LLOQ (n ¼ 5).
For IL-1b, 3 subjects had plasma concentrations below the LLOQ (n ¼ 10) and for TNF-a
8 subjects had plasma concentrations below the LLOQ (n ¼ 5).
Fig. 3. Results of 11,12-DiHETre after intraileal infusion (infusion time t ¼ 30e120 min)
with control (C), low-dose casein (LP) or high-dose casein (HP) (n ¼ 13). An effect for
time (p < 0.001), infusion (p < 0.001) and interaction between time and infusion
(p < 0.001) was found for 11.12-DiHETre. *p < 0.05 both LP and HP resulted in
decreased 11,12-DiHETre.
D. Ripken et al. / Clinical Nutrition xxx (2016) 1e76function, resulting in the release of pro-inﬂammatory cytokines
[12]. Another possible trigger for pro-inﬂammatory responses
when protein is not efﬁciently digested may be protein fermenta-
tion in the colon [11]. Therefore, it was reasonable to postulate that
ileal protein infusion could induce an inﬂammatory response.
However, in our study none of the pro-inﬂammatory cytokines
evaluated were affected by ileal infusion of 5 or 15 g casein.
Furthermore, almost the total amount of AAs infused as casein was
found in blood plasma suggesting that casein was already digested
before entering the colon. Additionally, none of the oxylipins
analyzed were induced by protein infusion, except for 11,12-
DiHETrE, which plasma concentrations decreased after infusion of
HP. Recently, increased plasma concentrations of 11,12-DiHETrE
have been found in patients with nonalcoholic steatohepatitis
(NASH), making it a candidate biomarker for the non-invasive
detection of NASH [23]. However, in our study the decrease of
11,12-DiHETrE was rather small and the exact function of this
oxylipin is still unknown. Therefore we believe this effect is has
little, if any, biological signiﬁcance.Please cite this article in press as: Ripken D, et al., Intraileal casein infu
randomized cross over trial, Clinical Nutrition (2016), http://dx.doi.org/1Several proteolytic enzymes, as well as the expression of pep-
tide- and amino acid-transporters (e.g. peptide transporter 1 and
B0AT1) are known to be present in the ileum [24e27]. These en-
zymes and transporters may be involved in the digestion and ab-
sorption of casein in the ileum. It was hypothesized that intraileal
infusion of native casein results in efﬁcient casein digestion and
absorption of casein speciﬁc AAs. It was found that LP and HP
resulted in recoveries of 72 ± 20% and 93 ± 13% for casein speciﬁc
AAs, suggesting that these AAs were indeed efﬁciently digested and
absorbed. To our knowledge, this is the ﬁrst study investigating the
effects of undigested proteins in the human ileum on its di-
gestibility. Previous studies evaluated postprandial kinetics and
digestibility of oral protein intake in healthy volunteers [9,28e30],
as well as casein digestibility after RYGB surgery [10]. Our estimated
AA recoveries after ileal protein infusion are in line with AA re-
coveries reported by Mahe et al. In that study orally ingested [15N]
caseinwas recovered in the jejunummainly in the form of peptides
and subsequently efﬁciently absorbed in the upper part of the small
intestine [28]. Luminal jejunal recovery of orally ingested casein
was 82.6 ± 9.5%. In another study by Gaudichon et al. (2002)
ingestion of a meal containing milk protein resulted in calculated
true digestibility percentages of AAs between 90 and 100% [30].
Although the recovery percentages in these studies are in the same
range as our ﬁndings on AA recoveries, direct comparisons are
difﬁcult. Both studies investigated the ingestion of oral protein
loads containing more protein as compared to the amounts of
protein infused in the present study e.g. 30 g milk protein [30] and
368 mmol casein [28] as compared to 5 or 15 g of casein in the
present study. Although the AA recovery of 15 g of ileal casein
infusion was approximately 80%, more studies are needed to
conﬁrm efﬁcient protein digestion and subsequent AA absorption
after intraileal delivery of higher amounts of protein.
This study has limitations that need to be considered. First, the
present study design was not optimal to draw conclusions on
amino acid digestion and absorption. Since we did not used labeled
casein protein we cannot prove that the increased AAs concentra-
tions were due to digestion and absorption of ileal infused casein.
Also we cannot exclude a possible interaction effect between
breakfast ingestion and casein infusion. Therefore, we can only
conclude that it is highly likely that the increased amino acid
plasma concentrations originated from casein digestion. Secondly,
data of the present study only concern acute responses. The effects
of repeatedly targeting the ileum with protein on adverse effects
remain to be investigated. However based on available literature of
patients undergoing RYGB it seems unlikely that repeatedly tar-
geting the ileum results in adverse effects or proteinmalabsorption.
A recent report showed that ingestion of caseinate by RYGB patientssion increases plasma concentrations of amino acids in humans: A
0.1016/j.clnu.2016.01.012
D. Ripken et al. / Clinical Nutrition xxx (2016) 1e7 7results in efﬁcient and even accelerated protein digestion and ab-
sorption as compared to protein ingestion before RYGB [10].
Furthermore, it has been proposed that malabsorption contributes
only a small proportion to the reduction in net energy absorption
which is observed after RYGB [4,7]. These data suggest that it is not
very likely that repeatedly targeting the ileum with native casein
results in adverse effects in healthy subjects. Thirdly, the present
study was performed with healthy subjects with a normal BMI and
may not give the same results in other groups, such as subjects with
comorbidities or overweight individuals. Fourthly, we only
measured a selection of inﬂammation parameters and therefore it
is possible that effects could have been missed.
Our group previously showed that intraileal infusion of casein,
sucrose and safﬂower oil results in increased satiation and
decreased food intake [3]. A reduction in food intake by ileal protein
infusion indicates that the ileal brake may be a target in the pre-
vention of overweight and obesity. The data of the present study
show that ileal casein infusion results in high plasma recoveries of
casein speciﬁc AA and does not induce acute adverse effects. These
data provide evidence that targeting the ileal brakemay not only be
a potent but also a safe target for weight management.
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